-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Monoclonal antibodies against the new coronavirus can specifically neutralize the new coronavirus, so it can be used for the treatment
of new coronavirus infection.
At present, the FDA has urgently authorized a number of new crown monoclonal antibodies
.
As mutant strains of the new coronavirus continue to emerge, especially the epidemic of Omicron, previously developed monoclonal antibodies may be less effective
.
As the pandemic continues, scientists have been developing new monoclonal antibodies to combat future variants of the virus
.
However, a new study shows that researchers developing monoclonal antibodies do not seem to have won the race
against the new coronavirus.
On November 18, 2022, researchers from the Leibniz Institute of Primatology in Germany published an article in the journal The Lancet Infectious Diseases entitled: Omicron sublineage BQ.
1.
1 resistance to monoclonal antibodies
。
The study showed that the new subtype BQ.
1.
1 of the new coronavirus Omicron is resistant to all known monoclonal antibody treatments
.
The research team looked at Omicron variants BJ.
1, BA.
4.
6, BA.
2.
75.
2 and BQ.
1.
1, as well as the effectiveness
of all currently available new crown monoclonal antibodies against them.
The results showed that all of these variants were resistant to some monoclonal antibody treatments, while BQ.
1.
1 was resistant to all monoclonal antibody treatments
.
This result is surprising because BQ.
1.
1 and BQ.
1 account for nearly half
of the recent new coronavirus infections in the United States.
It should be pointed out that monoclonal antibodies are usually only given to those with potential risks of serious complications, so BQ.
1.
1 is resistant to current monoclonal antibodies and has no substantial effect
on the vast majority of new crown infections.
However, the authors also note that monoclonal antibody therapy alone may not provide therapeutic efficacy in high-risk patients in areas where BQ.
1.
1 is being transmitted, and that other treatment options, such as Paxlovid orMolnupiravir
, should be considered.
In addition, for high-risk patients, there is an urgent need for novel monoclonal antibodies with broad-spectrum activity for prevention or treatment
.
Link to paper: Fulltext
is open for reprinting, welcome to forward to Moments and WeChat groups
of new coronavirus infection.
At present, the FDA has urgently authorized a number of new crown monoclonal antibodies
.
As mutant strains of the new coronavirus continue to emerge, especially the epidemic of Omicron, previously developed monoclonal antibodies may be less effective
.
As the pandemic continues, scientists have been developing new monoclonal antibodies to combat future variants of the virus
.
However, a new study shows that researchers developing monoclonal antibodies do not seem to have won the race
against the new coronavirus.
On November 18, 2022, researchers from the Leibniz Institute of Primatology in Germany published an article in the journal The Lancet Infectious Diseases entitled: Omicron sublineage BQ.
1.
1 resistance to monoclonal antibodies
。
The study showed that the new subtype BQ.
1.
1 of the new coronavirus Omicron is resistant to all known monoclonal antibody treatments
.
The research team looked at Omicron variants BJ.
1, BA.
4.
6, BA.
2.
75.
2 and BQ.
1.
1, as well as the effectiveness
of all currently available new crown monoclonal antibodies against them.
The results showed that all of these variants were resistant to some monoclonal antibody treatments, while BQ.
1.
1 was resistant to all monoclonal antibody treatments
.
This result is surprising because BQ.
1.
1 and BQ.
1 account for nearly half
of the recent new coronavirus infections in the United States.
It should be pointed out that monoclonal antibodies are usually only given to those with potential risks of serious complications, so BQ.
1.
1 is resistant to current monoclonal antibodies and has no substantial effect
on the vast majority of new crown infections.
However, the authors also note that monoclonal antibody therapy alone may not provide therapeutic efficacy in high-risk patients in areas where BQ.
1.
1 is being transmitted, and that other treatment options, such as Paxlovid orMolnupiravir
, should be considered.
In addition, for high-risk patients, there is an urgent need for novel monoclonal antibodies with broad-spectrum activity for prevention or treatment
.
Link to paper: Fulltext
is open for reprinting, welcome to forward to Moments and WeChat groups
